Direction at a glance
Lenacapavir has moved long-acting HIV prevention from a trial concept into guideline and regulatory implementation. The research question is now as much about equitable delivery, testing and persistence as biological efficacy.
What the evidence establishes
- WHO issued guidance for lenacapavir PrEP in 2025.
- The FDA approval record provides the regulated indication and conditions of use.
- Long dosing intervals can reduce the daily adherence burden, but do not remove the need for HIV testing and follow-up.
Next decisive research questions
Limits and responsible interpretation
What this direction does not yet prove
Approval and high trial efficacy do not guarantee access, affordability, uptake or population-level impact. Guidance remains jurisdiction specific.
Development pathway
| Decision | Required evidence |
|---|---|
| Biological activity | Target engagement and an outcome that cannot be explained by assay noise or selection. |
| Clinical value | Meaningful benefit, adequate follow-up, safety, comparison with current standard care and transparent uncertainty. |
| Generalizability | Diverse populations, subtypes, geographies, ages and clinically relevant comorbidities. |
| Scalability | Manufacturing, delivery, monitoring, price, workforce and community acceptability. |
Principal sources and evidence gateways
Links checked 18 August 202601
WHO guidelines on lenacapavir for HIV prevention and testing strategiesWorld Health Organization · Guideline · Access checked 18 Aug 2026
↗02FDA approval record for injectable lenacapavir for PrEPU.S. Food and Drug Administration · Regulatory record · Access checked 18 Aug 2026
↗03ClinicalTrials.gov HIV study registryU.S. National Library of Medicine · Registry · Access checked 18 Aug 2026
↗